SCHEMBL3223527

SCHEMBL3223527

CS(=O)(=O)c1ccc2c(c1)C(C(N)=O)=C[N]2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.39
AURKA O14965 1/20 0.37
ROCK2 O75116 1/20 0.37
CHEK2 O96017 1/20 0.37
CDK1 P06493 1/20 0.37
PIM1 P11309 1/20 0.37
FGFR3 P22607 1/20 0.37
CDK2 P24941 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
MAPK9 P45984 1/20 0.37
CSNK1D P48730 1/20 0.37
GSK3A P49840 1/20 0.37
RPS6KA3 P51812 1/20 0.37
LIMK1 P53667 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CDK5 Q00535 1/20 0.37
PRKCD Q05655 1/20 0.37
STK3 Q13188 1/20 0.37
ROCK1 Q13464 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222455 0.88 MAP4K4 (0.39) MAP4K4AURKAROCK2CHEK2CDK1
SCHEMBL3229587 0.76 KDM4E (0.33) KDRLMNAPTGDR2
SCHEMBL3219722 0.74 PARP1 (0.38) AURKAROCK2CHEK2CDK1PIM1
SCHEMBL7701338 0.74 PTGS2 (0.39) LMNAPTGDR2
SCHEMBL3227306 0.72 LMNA (0.39) MAP4K4AURKAROCK2CHEK2CDK1
SCHEMBL3222329 0.70 BCAT2 (0.38) FGFR3IKBKB
SCHEMBL3223520 0.67 LMNA (0.36) MAP4K4AURKAROCK2CHEK2CDK1
SCHEMBL22148182 0.64 G6PD (0.49) MAP4K4FLT4KDRPDE4BIKBKB
SCHEMBL4959356 0.64 MAPK1 (0.55) IKBKBCHUKLMNABRD4G6PD
SCHEMBL2911234 0.64 SMN1; SMN2 (0.49) PDE4BIKBKBCHUKLMNABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US claimed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP claimed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO claimed
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 MAP4K4 2134/4885AURKA 1400/4885ROCK2 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.